T-Rex 2X Long MSTR Daily Target ETF vs Regeneron Pharmaceuticals Inc — how do they compare? T-Rex 2X Long MSTR Daily Target ETF trades at $39.61 (market cap $809.00M), while Regeneron Pharmaceuticals Inc trades at $747.19 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 94.1× T-Rex 2X Long MSTR Daily Target ETF's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while T-Rex 2X Long MSTR Daily Target ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold T-Rex 2X Long MSTR Daily Target ETF for 18 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| MSTU | REGN | |
|---|---|---|
Market Cap | $809.00M | $76.14B |
Volume | 4,577,465 | 500,239 |
Sector | Leveraged / Inverse | Health |
52-Week High | $451.00 | $852.03 |
52-Week Low | $14.60 | $557.73 |
Typical Hold Time | 18 Days | 107 Days |
Enterprise Value | — | $70.85B |
Dividend Yield | — | 0.51% |
Signals from Pluang's Aura AI — not financial advice
MSTU trades at $40.50, up 2.66% with a bearish technical signal from moving averages while oscillators remain neutral. The stock faces significant resistance at $41-$43 levels with support at $37-$35. Recent corporate actions include a 10:1 reverse stock split effective August 24, 2026, and a $0.29 dividend declaration for H2-2026.
The leveraged ETF structure presents both opportunity and risk - offering amplified exposure to MSTR but with daily rebalancing that can erode value during volatility. Key risks include the compounding effect of daily leverage and Bitcoin price sensitivity. Investors should monitor the underlying stock's fundamentals and Bitcoin market dynamics closely.
Regeneron Pharmaceuticals (REGN) trades at $747.21, up 0.69% with strong recent earnings beats. The stock shows bearish technical signals but maintains robust fundamentals with 84.86% gross margins and consistent revenue growth. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, providing significant upfront and milestone payments. Analyst consensus remains strongly bullish with 69% buy ratings and an $849.84 price target, representing 13.7% upside potential from current levels.
REGN presents a compelling growth story with strong profitability and strategic partnerships, though technical indicators suggest near-term consolidation. The expanded Sanofi collaboration and promising clinical trial data provide catalysts, while competition in key therapeutic areas and reliance on blockbuster drugs represent ongoing risks. Wall Street optimism remains high given the company's execution track record and pipeline potential.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
MSTU is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bullish (long) position in MSTR, a company known for its significant Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on MSTU →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →